CHINA DONGXIANG (03818) announces interim results. The company's net profit attributable to shareholders reached 204 million RMB, a year-on-year growth of 48.9%.
China Trends (03818) announced its interim results for the six months ended September 30, 2025. Revenue is approximately 7.48...
China Dongxiang (03818) announced its interim performance for the six months ended September 30, 2025. The revenue was approximately 748 million yuan, a decrease of 0.1% year-on-year; gross profit was 511 million yuan, a decrease of 1% year-on-year; the profit attributable to owners of the company was 204 million yuan, an increase of 48.9% year-on-year; basic earnings per share were 3.47 cents, with proposed interim dividends and special interim dividends of 1.04 cents per ordinary share each, totaling 2.08 cents per share.
During the reporting period, the group continued to deepen the business models of "brand + product" and "brand + self-operation". On one hand, it further enhanced the brand value by integrating the brand advocacy culture into continuously upgrading products, building a solid brand influence; on the other hand, it continued to optimize and improve the new operational control model, optimize the distribution of self-operated networks, improve store efficiency, optimize e-commerce business, and better adapt to and meet consumer purchasing needs. At the same time, the group continued to adjust and optimize the self-operated stores, bringing the total number of Kappa brand stores to 975.
Related Articles

LIFE CONCEPTS (08056) issues profit warning, expecting a net loss of approximately HK$5 million for the mid-year.

On November 25th, MNSO(09896) spent approximately $245,900 to buy back 51,280 shares.

Betta Pharmaceuticals (300558.SZ): The registration application for Enzalutamide Hydrochloride Capsules for postoperative adjuvant therapy indications has been accepted.
LIFE CONCEPTS (08056) issues profit warning, expecting a net loss of approximately HK$5 million for the mid-year.

On November 25th, MNSO(09896) spent approximately $245,900 to buy back 51,280 shares.

Betta Pharmaceuticals (300558.SZ): The registration application for Enzalutamide Hydrochloride Capsules for postoperative adjuvant therapy indications has been accepted.

RECOMMEND

Foreign Brands “Take On Chinese Names”: Starbucks And Burger King Change Hands As Chinese Capital’s Localization Scalpel Rewrites Global Rules
25/11/2025

Riding The Momentum Of Gemini 3, “Google Chain” Challenges “Nvidia Chain,” Reshaping The Ai Trading Landscape
25/11/2025

Silver Economy Accelerates As Personal Pension System Marks Three Years — Structural Changes Emerging
25/11/2025


